| ￥4100 | |
| Z05722-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity | > 95% as determined by Bis-Tris PAGE | ||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Biological Activity | Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 75.84 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 110-140 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles. |
Immobilized OSMR beta-GPL fusion, His, Human, His Tag at 1 μg/ml (100 μl/well) on the plate. Dose response curve for Anti-OSMR Antibody, hFc Tag with the EC50 of 5.1ng/ml determined by ELISA. »
OSMR beta-GPL fusion, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | OSMR involvement, together with Gp130-like receptor (GPL), also known as IL-31R, in the formation of a functional IL-31 receptor complex. OSMR-GPL fusion protein was designed to contain the domains of OSMR and GPL required for high affinity IL-31 binding. |
| Synonyms | OSMR-GPL |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
